Premium
A study of the efficacy and safety of transurethral needle ablation (TUNA®) treatment for benign prostatic hyperplasia
Author(s) -
Millard R. J.,
Harewood L. M.,
Tamaddon K.
Publication year - 1996
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/(sici)1520-6777(1996)15:6<619::aid-nau3>3.0.co;2-i
Subject(s) - medicine , hyperplasia , benign prostatic hyperplasia (bph) , urology , tuna , ablation , animal study , prostate , surgery , fish <actinopterygii> , fishery , cancer , biology
The objective of this early phase III study was to determine the efficacy and safety of transurethral needle ablation (TUNA®) in patients presenting in acute urinary retention due to benign prostatic hyperplasia (BPH). Between September 1993 and August 1994, 20 patients of mean age 68.8 years were entered into a two‐center study and treated with TUNA® after presenting in acute urinary retention and having failed at least one trial of voiding. A mean of 5.4 lesions at shield temperatures of 54.6°C were produced. Patients were reviewed at 1, 3, 6, and 12 months (mean, 6.2 months). In 17 of 20 patients, voiding was reestablished in a mean of 2.6 days. Three patients required TURP for persistent retention, and 2 patients had delayed TURP for bothersome symptoms. Two voiders died later of unrelated causes. Five patients were lost to follow‐up at 6 months but were voiding when last reviewed. Symptom scores decreased from a mean of 19.0 (range 4–35) to 8.25 (range 1–20) at 12 months ( p = 0.06). Mean peak flow rate was 11.4 ml/sec (range 6.6–16.8) at 12 months ( p = 0.001). Mean prostatic volume at baseline was 65.8 cc and decreased to 56 cc at 12 months ( p = 0.111). The treatment was well tolerated by all patients, and side effects were mild, including urinary tract infection and epididymo‐orchitis. This study demonstrates the safety and effectiveness of TUNA® procedure in patients with urinary retention due to benign prostatic hypertrophy. © 1996 Wiley‐Liss, Inc.